Loading
Proclarix is a blood test from Onconetix for men whose PSA result is unclear. It gives a risk score to help decide whether a prostate biopsy is needed.
Proclarix, developed by Proteomedix and owned by Onconetix, is CE-marked and approved for sale in the European Union under the In Vitro Diagnostic Regulation. It is intended for men with elevated PSA in the diagnostic grey zone, where deciding whether a biopsy is needed is difficult. Onconetix cites a published 371-man cohort in which Proclarix ruled out clinically insignificant or absent prostate cancer with a low risk of missing clinically significant cancer, and a 2026 study of 132 men under active surveillance. In the United Kingdom a patient organisation offers it within a screening initiative, with about 100 tests carried out by 31 March 2026. Onconetix expects US marketing as a laboratory-developed test through Labcorp.
A multiparametric protein blood test run on the same sample as a PSA test, which combines its markers into the Proclarix Risk Score to help decide whether a biopsy is needed in men with PSA in the diagnostic grey zone, as described by Onconetix.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Proclarix" OR ABSTRACT:"Proclarix") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Proclarix, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/